<DOC>
	<DOCNO>NCT02180477</DOCNO>
	<brief_summary>Study investigate relative bioavailability UHAC 62 XX capsule two different tablet formulation ( TF1 TF2 ) , obtain data rational design subsequent pivotal bioequivalence ( BE ) study capsule tablet formulation .</brief_summary>
	<brief_title>Preliminary Bioequivalence Study UHAC 62 XX Tablets Compared With Capsule Formulation Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Age &gt; = 20 &lt; = 35 year Weight : BMI &gt; = 18.5 &lt; 25 ( Weight ( kg ) / Height ( mÂ² ) Subjects judged investigator appropriate subject study base result screen test Subjects volunteer participate able fully understand agree study write informed consent History gastrointestinal ulcer surgery gastrointestinal tract ( except appendectomy ) History hypersensitivity meloxicam and/or salicylate ( aspirin ) and/or Nonsteroidal antiinflammatory drug ( NSAIDs ) History aspirin induce asthma ( bronchial asthma induce NSAIDs ) History alcohol drug abuse Participation another trial investigational drug within 4 month prior administration Whole blood donation 400 ml within 3 month prior administration Whole blood donation 100 ml within 1 month prior administration Donation constituent blood 400 ml within 1 month prior administration Any medication within 10 day prior administration Excessive physical activity within 7 day prior administration Alcohol drinking within 3 day prior administration History orthostatic hypotension , faint spell blackouts Other , judged investigator inappropriate subject study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>